Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, talks about how factors such as the sedative effects of anti-epileptic medications can mask sleep issues and diagnoses in people with epilepsy.
Milena Pavlova, MD, neurologist, and medical director of the sleep testing center at Brigham and Women’s Faulkner hospital, talks about how such factors as too little time in an appointment to screen for sleep as one of many possible reasons sleep disorders are underdiagnosed in people with epilepsy.
This interview took place at the American Academy of Neurology 75th annual meeting in Boston, MA.
Transcript
Are sleep disorders underdiagnosed in people with epilepsy? If so, why?
Yes, is the short answer. Why is always a complex question, no matter what you're talking about. I feel that sleep has traditionally been undervalued by physicians, for one obvious reason. We go through a very strenuous process of residency during which we are implicitly told the sleep doesn't matter, because we don't get to sleep much.
That kind of joke aside, a patient with epilepsy has a chronic disease that requires a lot of complex treatment. There is the treatment with medications, there is the consequence of seizures, there is the consequence of having a chronic disease that affects your consciousness, and all the implications of this. So, it is a complex treatment altogether. Somehow sleep, it's just one component of many different things than the physician has to do. So, that's one reason; they simply might not have enough time to ask about the sleep of the patients.
The second thing is that some of the signs of sleep disorders can be attributed to something else. Because when a patient with frequent seizures has a seizure, often they would be afterward sleepy or confused. So, whatever sleepiness the patient reports can often be attributed to just uncontrolled seizures, appropriately so, but there might be a contributing factor of a sleep disorder. Another thing is that most of the anti-epileptic medications have more or less of a sedating effect. So, a lot of the times the symptoms of sleepiness is attributed to the sedating effect.
Having a chronic disease altogether can make you a little bit more anxious; a little bit more difficult to sleep at night. The whole process of having seizures during the daytime, potentially disrupting the regularity of sleep and wakefulness, can be another reason for poor sleep. So, a lot of the times the sleep complaint gets attributed to something else; that is very common in patients with epilepsy.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
2 Commerce Drive
Cranbury, NJ 08512